Biotechnology News and Research

RSS

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform.

19 May 2015

Simple blood test can predict evidence of TBI on radiographic imaging, injury severity

New study results show that a simple blood test to measure brain-specific proteins released after a person suffers a traumatic brain injury (TBI) can reliably predict both evidence of TBI on radiographic imaging and injury severity.

19 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

Acupuncture reduces pain, inflammation in pediatric patients with acute appendicitis

Acupuncture was shown to lessen pain and reduce the underlying inflammation in pediatric patients with a diagnosis of acute appendicitis, according to a study published in the Journal of Alternative and Complementary Medicine, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

15 May 2015

Denali launched to discover, develop effective medicines for neurodegenerative diseases

Denali Therapeutics Inc., a new biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that it has launched with an initial investment commitment of $217 million.

14 May 2015

ZenBio, Inc. introduces GroPro™ Cell Culture Growth Supplement formulated  to replace Bovine serum

ZenBio, Inc. industry leader in robust cell-based solutions, announced today the worldwide release of a new GroPro Cell Culture Growth Supplement...

14 May 2015

BrainStorm Cell Therapeutics reports financial results for Q1 2015, provides business update

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.

14 May 2015

LABINDIA to promote Dotmatics’ scientific informatics solutions, services in India

Dotmatics, the leading provider of scientific informatics solutions and services for the pharma, biotech, chemicals, agrochemicals and academia announced today that it has appointed LABINDIA as a distributor in India.

14 May 2015

Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

In a new study published in the Protein & Cell, Chen-Yu Zhang's group at Nanjing University reports that small non-coding RNAs in maternal food can transfer through placenta to regulate fetal gene expression.

14 May 2015

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen.

13 May 2015

Inoviem Scientific receives €545,000 from French public investment bank bpifrance

Inoviem Scientific, a Contract Research Biotech (CRB) company today announces that it has received additional funding of €545,000 ($611,000) from French public investment bank bpifrance. The company leverages two proprietary technologies to offer pharmaceutical players increased speed and enhanced safety at all stages of drug development; from drug discovery (the identification of secondary targets and detection of potential adverse effects, etc.) through to clinical trials (with patient stratification and identification of biomarkers, etc.).

12 May 2015

China Pharma revenue decreases 20% to $5.7 million in Q1 2015

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended March 31, 2015.

12 May 2015

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

11 May 2015

BHI awarded NIH contract to provide mentoring and training for NINDS grantees

BioHealth Innovation, Inc. is providing grantees of the National Institute of Health's National Institute of Neurological Disorders and Stroke with mentoring and training designed to develop and hone their presentation skills as a step toward securing investment dollars and strategic partners.

11 May 2015

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

11 May 2015

Calcivis Caries Activity Imaging System meets primary performance endpoint in first clinical study

Calcivis, a medical devices company focused on revolutionising the management of tooth decay and enabling preventive dentistry, today announces headline results from the first clinical study of its Calcivis® Caries Activity Imaging System.

11 May 2015

GenVec reports net loss of $1.5 million for first quarter 2015

GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.

8 May 2015

TESCAN introduce unique multimodal holographic microscope for live cell imaging

The unique Q-PHASE microscope is based on the principle of incoherent holography. Where other available solutions make use of a laser or laser diode, which may cause adverse or undesirable effects, mainly in terms of imaging quality, Q-PHASE uses white light for illumination, thus producing high quality imaging...

From Tescan 8 May 2015

Gene therapy is key to addressing Sanfilippo Syndrome, say Ohio scientists and clinicians

Gene therapy is the delivery of DNA into a patient's cells to replace faulty or missing genes—or adds new genes—in an attempt to cure cancer or make changes so the body is better able to fight off disease. Scientists and clinicians have identified a number of different ways to do this, in an effort to correct malfunctioning or mutated genes. Many gene therapy clinical trials are ongoing to assess the safety and potential benefits in patients with rare diseases.

8 May 2015

Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen GmbH, a biotechnology company developing anti-infective drugs, today announced the signing of a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas.

7 May 2015

Biotechnology News and Research

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

Simple blood test can predict evidence of TBI on radiographic imaging, injury severity

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Acupuncture reduces pain, inflammation in pediatric patients with acute appendicitis

Denali launched to discover, develop effective medicines for neurodegenerative diseases

ZenBio, Inc. introduces GroPro™ Cell Culture Growth Supplement formulated  to replace Bovine serum

BrainStorm Cell Therapeutics reports financial results for Q1 2015, provides business update

LABINDIA to promote Dotmatics’ scientific informatics solutions, services in India

Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

Soligenix, Emergent BioSolutions sign development agreement

Inoviem Scientific receives €545,000 from French public investment bank bpifrance

China Pharma revenue decreases 20% to $5.7 million in Q1 2015

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

BHI awarded NIH contract to provide mentoring and training for NINDS grantees

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Calcivis Caries Activity Imaging System meets primary performance endpoint in first clinical study

GenVec reports net loss of $1.5 million for first quarter 2015

TESCAN introduce unique multimodal holographic microscope for live cell imaging

Gene therapy is key to addressing Sanfilippo Syndrome, say Ohio scientists and clinicians

Cyclenium Pharma, Haplogen sign agreement to discover novel pharmaceutical candidates

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News